Literature DB >> 18794387

Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis.

Verena Hafner1, Nadine Albermann, Walter E Haefeli, Friedrich Ebinger.   

Abstract

For an adolescent with bacterial meningitis and subsequent cerebral aspergillosis, intravenous voriconazole dose requirements substantially decreased during coadministration with intravenous chloramphenicol and considerably rose after discontinuation of the antibiotic. In agreement with in vitro evidence, these data suggest that chloramphenicol is a rather significant inhibitor of hepatic CYP3A4 and/or CYP2C19.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18794387      PMCID： PMC2573136          DOI： 10.1128/AAC.00805-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient.

Authors:  D J Taber; R E Dupuis; K D Hollar; A L Strzalka; M W Johnson
Journal:  Transplant Proc       Date:  2000-05       Impact factor: 1.066

2.  Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.

Authors:  Thomas J Walsh; Irja Lutsar; Timothy Driscoll; Bertrand Dupont; Maureen Roden; Parvis Ghahramani; Michael Hodges; Andreas H Groll; John R Perfect
Journal:  Pediatr Infect Dis J       Date:  2002-03       Impact factor: 2.129

3.  Interaction of chloramphenicol and the calcineurin inhibitors in renal transplant recipients.

Authors:  A S Mathis; N Shah; G T Knipp; G S Friedman
Journal:  Transpl Infect Dis       Date:  2002-09       Impact factor: 2.228

4.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

5.  Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes.

Authors:  Ji-Young Park; Kyoung-Ah Kim; Su-Lyun Kim
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration.

Authors:  Bernhards R Ogutu; Charles R J C Newton; Simon N Muchohi; Godfrey O Otieno; Gilbert O Kokwaro
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

7.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.

Authors:  R Hyland; B C Jones; D A Smith
Journal:  Drug Metab Dispos       Date:  2003-05       Impact factor: 3.922

8.  Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole.

Authors:  Lynn Purkins; Nolan Wood; Diane Kleinermans; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

9.  Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.

Authors:  Nolan Wood; Keith Tan; Lynn Purkins; Gary Layton; Julia Hamlin; Diane Kleinermans; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

10.  Voriconazole plasma monitoring.

Authors:  A C Pasqualotto; M Shah; R Wynn; D W Denning
Journal:  Arch Dis Child       Date:  2008-02-05       Impact factor: 3.791
View more
  3 in total

1.  The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis.

Authors:  S Schwartz; A Reisman; P F Troke
Journal:  Infection       Date:  2011-04-22       Impact factor: 3.553

2.  Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.

Authors:  Maud Berge; Romain Guillemain; David A Trégouet; Catherine Amrein; Veronique Boussaud; Patrick Chevalier; Agnes Lillo-Lelouet; Christine Le Beller; Pierre Laurent-Puig; Philippe H Beaune; Eliane M Billaud; Marie-Anne Loriot
Journal:  Eur J Clin Pharmacol       Date:  2010-10-31       Impact factor: 2.953

3.  Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.

Authors:  H-R He; J-Y Sun; X-D Ren; T-T Wang; Y-J Zhai; S-Y Chen; Y-L Dong; J Lu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-17       Impact factor: 3.267
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.